Compare Cytokinetics Inc (CYTK) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Firy Inc. — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while Firy Inc. trades at $12.04 (market cap $199.80M). The key difference: Cytokinetics Inc is far larger — about 43.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Firy Inc. for 13 Days on average.
| CYTK | FIRY | |
|---|---|---|
Market Cap | $8.62B | $199.80M |
Volume | 2,594,626 | 92,993 |
Sector | Health | Technology |
52-Week High | $87.26 | $13.10 |
52-Week Low | $54.76 | $2.28 |
Typical Hold Time | 19 Days | 13 Days |
Enterprise Value | $8.72B | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
FIRY trades at $12.18, up 2.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Despite a high gross margin of 87.76%, profitability remains challenged with negative net income margin and ROE. Recent developments include a $719 million legal victory and board appointment of Marc Lasry.
The outlook remains cautious due to persistent cash burn and negative earnings, though the legal win provides potential upside. Investment opportunity hinges on successful monetization of legal claims and operational turnaround. Key risks include ongoing cash flow deficits, competitive pressures, and uncertainty around debt collection from Papaya Gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
